Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Children's Medical Safety Research Institute Announces Innovative Study on Alzheimer’s Treatment Is Subject of Crowd Funding Campaign
  • USA - English


News provided by

Children's Medical Safety Research Institute

Jul 29, 2015, 03:00 ET

Share this article

Share toX

Share this article

Share toX


Washington, DC (PRWEB) July 29, 2015 -- One of the world’s leading experts on aluminum and aluminum-related illnesses is seeking funding for a study on the potentially lifesaving impact of removing aluminum from Alzheimer’s disease patients, announced the Children’s Medical Safety Research Institute today.

There have not been any significant advances in the treatment of Alzheimer’s disease for 40 years. We are now in position to establish if aluminum plays a role in the disease and if it does, we will have an effective strategy for treating people with it.

Post this

The research proposal is based on a successful pilot study published in The Journal of Alzheimer’s Disease in 2013 that demonstrated clinically-significant improvement in cognitive function in some Alzheimer’s patients after ingestion of silicon-rich mineral water (which aids in the excretion of aluminum) over a 12-week period.

This discovery, representing the first time any treatment has been shown to be effective for Alzheimer’s patients, was made by researchers at Keele University in Staffordshire, England, led by Professor of Bioinorganic Chemistry Christopher Exley. Exley has been a pioneer in the study of aluminum toxicity and silicon for over 30 years and was the first to show that the toxicity of fish can be completely removed in the presence of silicon. He has since demonstrated the same for humans. A recipient of a prestigious Royal Society University Research Fellowship, Exley has published over 150 scientific papers and has been the Principal or Chief Investigator in two previous Alzheimer’s trials and others involving Parkinson’s disease, multiple sclerosis, macrophagic myofasciitis and premature babies.

Exley and his research team believe that the weight of evidence implicating aluminum in Alzheimer’s disease is so unequivocal that the effect of silicon in helping the body to excrete aluminum and reverse the effects of the disease must be tested in a large scale clinical trial. In it, early-stage Alzheimer’s disease patients will be recruited to drink at least a liter of silicon-rich mineral water every day for up to 24 months. During this time, Exley and his team will carefully monitor the state and/or the progression of memory and cognition degradation to determine if there is statistically valid proof of a contributory role for aluminum in Alzheimer’s disease.

The trial has been fully endorsed by the Editor-in-Chief of the Journal of Alzheimer’s Disease, George Perry, Ph.D.

“There are many in the medical field who have given up on finding the cause of Alzheimer’s, but we have not,” said Dr. Exley, who has published previous research on the toxicity of aluminum and Alzheimer’s. “There have not been any significant advances in the treatment of Alzheimer’s disease for 40 years. We are now in position to establish if aluminum plays a role in the disease and if it does, we will have an effective strategy for treating people with it.”

The scale of the study, referred to as “The People’s Trial,” has necessitated a public appeal for financial support which is being conducted through the crowd funding website, “Futsci” (short for Future science). A research proposal and video about the study can be found at https://www.futsci.com/project/the-aluminium-alzheimer-s-disease-hypothesis-what-is-the-role-of-aluminium-in-alzheimers-disease.

The 3-month fundraising campaign will be continue until September 20, 2015. If, at its conclusion, insufficient funds are raised, all donations will be returned to donors.

“Many of us have already been impacted in some way by Alzheimer’s disease and we know that it could affect us or someone close to us,” said Dr. Exley. “Now is the time when we can all make a difference. This is why I believe in this clinical trial and why I am asking you all to support it.”

An estimated 5.2 million Americans are living with Alzheimer’s disease today and care for them is expected to reach $1 trillion each year in the coming decades if the current rapid rate of growth continues.

About CMSRI

The Children’s Medical Safety Research Institute is a medical and scientific collaborative established to provide research funding for independent methodologically sound controlled scientific research on causal factors underlying the chronic disease and disability epidemic. The 501(c)(3) non-profit organization is publicly funded and 100% of donations support new CMSRI research. http://www.cmsri.org

Questions? Contact Karen Baratz at karen(at)baratzpr(dot)com.

Karen Baratz, Children's Medical Safety Research Institute, http://www.cmsri.org/, +1 888-932-4629 Ext: 117, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.